<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003867" GROUP_ID="SYMPT" ID="063800101310051475" MERGED_FROM="" MODIFIED="2017-08-21 12:10:59 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="53" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2017-08-21 12:10:06 +0100" MODIFIED_BY="Anna Erskine">
<TITLE>Single dose dipyrone for acute renal colic pain</TITLE>
<CONTACT>
<PERSON ID="67250691596112646583120822083255" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Anna</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Erskine</LAST_NAME>
<SUFFIX/>
<POSITION>Managing Editor</POSITION>
<EMAIL_1>anna.erskine@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://papas.cochrane.org/</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Pain, Palliative and Supportive Care Group</DEPARTMENT>
<ORGANISATION>Pain Research Unit</ORGANISATION>
<ADDRESS_1>The Churchill Hospital</ADDRESS_1>
<ADDRESS_2>Old Road</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225762</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-08-21 12:09:47 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="4D32DC6982E26AA20145240A91884D05" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jayne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Edwards</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Training Team</DEPARTMENT>
<ORGANISATION>UK Cochrane Centre</ORGANISATION>
<ADDRESS_1>National Institute for Health Research</ADDRESS_1>
<ADDRESS_2>Summertown Pavilion, Middle Way</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX2 7LG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 516300</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 516311</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15661" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Fuensanta</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Meseguer</LAST_NAME>
<SUFFIX/>
<POSITION>Servicio de Anestesiología</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Reanimación y Tratamiento del Dolor</DEPARTMENT>
<ORGANISATION>Hospital Reina Sofía</ORGANISATION>
<ADDRESS_1>General Universitario de Murcia</ADDRESS_1>
<ADDRESS_2/>
<CITY>Murcia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Clara</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Faura</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>faura@umh.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Instituto de Neurosciences</DEPARTMENT>
<ORGANISATION>Universidad Miguel Hernandaz</ORGANISATION>
<ADDRESS_1>Campus San Juan</ADDRESS_1>
<ADDRESS_2/>
<CITY>Alicante</CITY>
<ZIP>03550</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 96 5919 489</PHONE_1>
<PHONE_2/>
<FAX_1>+34 96 5919 561</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7899" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>R Andrew</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moore</LAST_NAME>
<SUFFIX>DSc</SUFFIX>
<POSITION>Research Director</POSITION>
<EMAIL_1>andrew.moore@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225401</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7877" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Henry</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>McQuay</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Pain Research</POSITION>
<EMAIL_1>henrymcquay@gmail.com</EMAIL_1>
<EMAIL_2>henrymcquay@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>West Wing (Level 6)</ADDRESS_1>
<ADDRESS_2>John Radcliffe Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 9DU</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 231515</PHONE_1>
<PHONE_2>+44 1865 851138</PHONE_2>
<FAX_1>+44 1865 223844</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5475F46C82E26AA20187B79619319C6E" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sheena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Derry</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Officer</POSITION>
<EMAIL_1>sheena.derry@ndcn.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT>
<ORGANISATION>University of Oxford</ORGANISATION>
<ADDRESS_1>Pain Research Unit</ADDRESS_1>
<ADDRESS_2>Churchill Hospital</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 7LE</ZIP>
<REGION>Oxfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 225405</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 225402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-04-20 15:58:55 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="20" MONTH="4" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="1" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-21 12:10:06 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-21 12:10:06 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="21" MONTH="8" YEAR="2017"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2011-04-20 15:59:45 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>The review authors have declared that there are unlikely to be any new RCTs to affect the conclusions of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-08-21 12:09:59 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-21 12:09:59 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="26" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-04-20 15:58:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-08 10:49:26 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="24" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-24 11:32:05 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="4" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>Re-published with Jayne Rees reverted to Jayne Edwards to match citations of her Cochrane reviews appearing outside the Cochrane Library</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-24 11:32:05 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="28" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Pain Research Funds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Boehringer Ingelheim Laboratories, Madrid</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-04-20 16:05:54 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-05-28 14:27:17 +0100" MODIFIED_BY="Sheena Derry">
<TITLE MODIFIED="2008-05-28 14:27:17 +0100" MODIFIED_BY="Sheena Derry">Single dose dipyrone for acute renal colic pain</TITLE>
<SUMMARY_BODY>
<P>Renal colic pain is extremely painful and requires immediate treatment with strong analgesics. Dipyrone is a non-opioid analgesic widely used for this purpose but not licensed in some countries (e.g., USA, UK) because of potentially fatal side effects (agranulocytosis). This review aimed to assess the effectiveness and safety of single dose dipyrone in adults with moderate/severe renal colic pain but there were too few data to obtain clear results. The data available indicated that intravenous dipyrone was more effective than intramuscular dipyrone, and combining dipyrone with antispasmolytic agents did not improve its efficacy. Commonly reported side effects included dry mouth and drowsiness, and some patients experienced pain at the injection site. Agranulocytosis was not reported.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-28 14:35:55 +0100" MODIFIED_BY="Sheena Derry">
<ABS_BACKGROUND>
<P>Renal colic pain is extremely painful and requires immediate treatment with strong analgesics. Dipyrone is the most popular non-opioid first line analgesic in many countries but in others it has been banned (e.g. USA, UK) because of its association with blood dyscrasias such as agranulocytosis. Since dipyrone is used in many countries (e.g. Brazil, Spain) there is a need to determine the benefits and harms of its use to treat renal colic pain.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-05-28 14:35:05 +0100" MODIFIED_BY="Sheena Derry">
<P>Assess quantitatively the analgesic efficacy and adverse effects of single-dose dipyrone in adults with moderate to severe renal colic pain.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-05-28 14:35:22 +0100" MODIFIED_BY="Sheena Derry">
<P>Published reports were identified from electronic databases (MEDLINE, EMBASE, <I>The Cochrane Library</I>, LILACS) and additional studies were identified from the reference lists of retrieved reports. Date of the most recent search: January 2000.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Inclusion criteria were: full journal publication; RCT with a double-blind design; adult patients with baseline renal colic pain of moderate or severe intensity; treatment arms which included dipyrone (oral, intramuscular or intravenous administration) and a control; single dose data.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Summed pain intensity and pain relief data were extracted and converted into dichotomous information to yield the number of patients with at least 50% pain relief over 15-30 minutes, 1-2 hours and six hours. The proportion of patients with at least 50% pain relief was calculated. Single dose adverse effect data were collected.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-28 14:35:55 +0100" MODIFIED_BY="Sheena Derry">
<P>Eleven studies with 1053 patients (550 on dipyrone) met the inclusion criteria. Unfortunately, few data were available for analysis; most analyses were based on the results of single, small trials and statistical pooling of the results was inappropriate. Efficacy estimates were calculated as the weighted mean percent of patients achieving at least 50% pain relief with the range of values from trials contributing to the analysis. However, these estimates were not robust. Commonly reported adverse effects with intravenous dipyrone were dry mouth and somnolence, and one study reported pain at the injection site. Insufficient information was available for safety analyses.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Limited available data indicated that single dose dipyrone was of similar efficacy to other analgesics used in renal colic pain, although intramuscular dipyrone was less effective than diclofenac 75 mg. Combining dipyrone with antispasmolytic agents did not appear to improve its efficacy. Intravenous dipyrone was more effective than intramuscular dipyrone. Dry mouth and somnolence were commonly reported with intravenous dipyrone. None of the studies reported agranulocytosis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-04-20 16:05:54 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-04-20 16:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>Renal colic pain is excruciating. It requires immediate and effective treatment with strong analgesics such as opioids, either alone or in combination with spasmolytic agents. Pethidine and morphine are frequently used.</P>
<P>Prostaglandins are thought to be involved in the pathogenesis of renal colic pain. Prostaglandin-synthetase inhibitors, such as indomethacin and diclofenac sodium, have produced beneficial results (<LINK REF="REF-Quilez-1984" TYPE="REFERENCE">Quilez 1984</LINK>).</P>
<P>Phenazones, including dipyrone, are not impressive anti-inflammatory or antirheumatic agents. The inflammatory process increases the sensitivity of nociceptors in the tissue and alters the neuronal activity in the dorsal horn of the spinal cord (wind up phenomena) (<LINK REF="REF-Besson-1987" TYPE="REFERENCE">Besson 1987</LINK>; <LINK REF="REF-Foster-1992" TYPE="REFERENCE">Foster 1992</LINK>; <LINK REF="REF-Schaible-1985" TYPE="REFERENCE">Schaible 1985</LINK>). Dipyrone appears to mediate its analgesic effects in the spinal cord, where it reduces prostaglandin production. A normalisation of the inflammation-related pain occurs producing 'wind up phenomena'. Since dipyrone does not accumulate in the tissue, it should lack the adverse gastrointestinal and renal effects associated with anti-inflammatory drugs.</P>
<P>Dipyrone also exhibits a pronounced spasmolytic effect (<LINK REF="REF-Arrellano-1990" TYPE="REFERENCE">Arrellano 1990</LINK>). High-doses of intravenous or intramuscular dipyrone, alone or in combination with other drugs, are commonly used (Lloret 1987a). Such therapeutic regimens have been shown to be effective (<LINK REF="REF-ESPSCP-1991" TYPE="REFERENCE">ESPSCP 1991</LINK>).</P>
<P>Dipyrone is the most popular non opioid first line analgesic in many countries. It is currently available in Austria, Belgium, France, Germany, India, Israel, Italy, the Netherlands, Russia, Spain, South Africa, South America and Switzerland, but its use has been banned in the USA and UK because of its association with blood dyscrasias, e.g. agranulocytosis. Agranulocytosis is a rare, but serious adverse effect which can occur in the acute treatment phase. It results in a rapid depletion of granulocytes and may be fatal.</P>
<P>Since dipyrone is widely used, particularly in countries like Brazil and Spain, there is a need to determine how effective it is in the treatment of renal colic pain and what adverse effects it causes.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate quantitatively the analgesic efficacy and adverse effects of single doses of dipyrone in adults with moderate or severe renal colic pain. </P>
</OBJECTIVES>
<METHODS MODIFIED="2011-04-20 16:02:41 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Reports were included if they were: full journal publications of single dose, double blind, randomised controlled trials of dipyrone in renal colic pain. Multiple dose studies were included if they provided single dose data. Study drugs needed to have been administered (by intramuscular or intravenous injection or orally) to adult patients with moderate or severe pain at the baseline assessment. </P>
<P>Reports were excluded if they did not clearly state that study medication had been randomly allocated or if the method of randomisation was considered inappropriate (e.g. date of birth), or if they examined other pain conditions (e.g. biliary colic). Abstracts, review articles, case reports and clinical observations were also excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Trials with adult patients (individuals over the age of 15) with established renal colic pain of moderate or severe intensity at the baseline assessment were included in this review. Patients entered in the trials had an episode of acute renal colic described as colicky pain in the flank and/or radiating to the homolateral hemi-abdomen and /or genitalia, with or without vegetative symptoms. Diagnosis was based on clinical signs or symptoms, with renal or ureteral calculi identified by abdominal radiography in some trials.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Reports were included if they contained a treatment group allocated to either dipyrone (single dose) compared with placebo or an active control. Oral, intramuscular or intravenous routes of administration were included. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Data were collected on the following outcomes:</P>
<UL>
<LI>patient characteristics</LI>
<LI>patient reported pain at baseline (physician, nurse, or carer reported pain was excluded from the analysis)</LI>
<LI>patient reported pain relief expressed using validated pain scales (pain intensity and pain relief in the form of visual analogue scales and /or categorical scales) over 15-30 minutes, one to two hours and six hours </LI>
<LI>time to remedication</LI>
<LI>use of rescue medication</LI>
<LI>withdrawals - discontinuation of treatment for any reason</LI>
<LI>adverse effects - major and minor</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-04-20 16:01:29 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-04-20 16:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>The Cochrane Library </I>(Issue 3 1999), MEDLINE (1966 to October 1999), EMBASE (1980 to October 1999), LILACS (January 2000), the Oxford Pain Relief Database (<LINK REF="REF-Jadad-1996a" TYPE="REFERENCE">Jadad 1996a</LINK>) and the Internet were searched to identify published reports of randomised controlled trials (RCTs) which assessed dipyrone in renal colic pain.</P>
<P>A broad free text search was used without language restriction to identify the maximum possible number of citations. Search terms used were a combination of those seen in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Information about ongoing clinical trials was sought by searching the new clinical trials site from the National Institute of Health (http://clinicaltrials.gov).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-04-20 16:01:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>Additional citations were retrieved from checking reference lists of retrieved reports.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Personal contact</HEADING>
<P>Pharmaceutical companies, study authors, experts, and the Iberoamerican and Brazilian Cochrane Centres were contacted about unpublished data.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-04-20 16:02:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>Two review authors (JE, FM) independently assessed studies for inclusion in this review. There was no attempt at anonymisation of the reports before assessment. A consensus meeting was held with all authors to agree the papers for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two review authors (JE, FM) independently carried out data abstraction and quality assessments. Again, a consensus meeting was held with all authors to agree the assessments for each included study.<BR/>
<BR/>The following items were extracted:</P>
<P>(i) the number of patients treated<BR/>(ii) dichotomous information (e.g. number of patients with at least 50% pain relief) if presented<BR/>(iii) mean TOTPAR, SPID, VAS TOTPAR or VAS SPID<BR/>(iv) study duration<BR/>(v) the dose of dipyrone<BR/>(vi) the route of administration of study drugs<BR/>(vii) information on adverse effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis</HEADING>
<P>TOTPAR (total pain relief) or SPID (summed pain intensity difference) over 15-30 minutes, one to two hours, and six hours or sufficient data to allow their calculation were extracted.</P>
<P>The pain outcome measures allowed for the calculation of TOTPAR and SPID were:</P>
<UL>
<LI>a five point categorical pain relief scale with comparable wording to 'none, slight, moderate, good, complete' (scales using percentages as anchors were not permitted</LI>
<LI>four point categorical pain intensity scale with comparable wording to 'none, mild, moderate, severe'</LI>
<LI>VAS 100 mm for pain intensity</LI>
<LI>VAS 100 mm for pain relief</LI>
<LI>patient's global evaluation using a standard 5-point scale (poor, fair, good, very good, excellent)</LI>
</UL>
<P>When dichotomous information (number or proportion of patients with at least 50% pain relief) was available this was extracted.</P>
<P>For visual analogue scales (VAS) pain of at least moderate intensity equates to greater than 30 mm on a 100 mm VAS (<LINK REF="REF-Collins-1997" TYPE="REFERENCE">Collins 1997</LINK>). When the baseline pain intensity was presented as a mean VAS score with the corresponding standard deviation, the data were only included in the analysis if the mean minus 1.96 times the standard deviation was greater than 30 mm.</P>
<P>A global rating of the effect of a single dose of study medication was extracted when no other information was available. Only the patient's global evaluation using a standard 5-point scale (poor, fair, good, very good, excellent) was allowed, and dichotomous information was extracted for the top two categories (very good and excellent). Information from the top two categories of the patient global rating has been shown to produce very similar estimates of analgesic efficacy to information from standard pain relief and pain intensity measurement scales (<LINK REF="REF-Collins-2001" TYPE="REFERENCE">Collins 2001</LINK>).</P>
<P>Where pain outcomes were reported only as mean values, mean TOTPAR, SPID, VAS TOTPAR and VAS SPID values were converted to %maxTOTPAR or %maxSPID by division into the calculated maximum value (<LINK REF="REF-Cooper-1991" TYPE="REFERENCE">Cooper 1991</LINK>). Verified equations were used to estimate the proportion of patients achieving at least 50% maxTOTPAR (<LINK REF="REF-Moore-1996" TYPE="REFERENCE">Moore 1996</LINK>; <LINK REF="REF-Moore-1997a" TYPE="REFERENCE">Moore 1997a</LINK>; <LINK REF="REF-Moore-1997b" TYPE="REFERENCE">Moore 1997b</LINK>). This was then converted to the number of patients achieving at least 50% maxTOTPAR (pain relief) by multiplying by the total number of patients in the treatment group. Because this method has been used to calculate the efficacy of a number of different drugs, this allowed the efficacy of dipyrone to be compared with other pain relief treatments.</P>
<P>Weighted means (by study size) were calculated.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-04-20 16:05:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-04-20 16:03:15 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-six studies were identified as potential randomised controlled trials of dipyrone or dipyrone plus a spasmolytic agent for the treatment of acute renal colic pain.</P>
<P>Of those 26, one study could not be obtained (<LINK REF="REF-Victorov-1978" TYPE="REFERENCE">Victorov 1978</LINK>) and 14 were excluded as follows:<BR/>
</P>
<UL>
<LI>eight were not double blind</LI>
<LI>three were not randomised</LI>
<LI>one was a duplicate publication (<LINK REF="STD-Muriel-1993" TYPE="STUDY">Muriel 1993</LINK>)</LI>
<LI>two had no extractable data.</LI>
</UL>
<P>Information on the excluded studies is provided in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<P>Eleven studies met the inclusion criteria. These studies enrolled a total of 1053 patients on all treatments; 550 of these were treated with dipyrone. Also assessed were a number of doses of dipyrone (alone or combined with spasmolytic agents) administered by intramuscular or intravenous routes. Details are given in the 'Characteristics of Included Studies' table as well as in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-04-20 16:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>Each included study was scored for quality using a three-item scale (<LINK REF="REF-Jadad-1996b" TYPE="REFERENCE">Jadad 1996b</LINK>) as follows:</P>
<P>Is the study randomised? If yes then 1 point<BR/>Is the randomisation procedure reported and is it appropriate? If yes then add 1 point, if not deduct 1<BR/>Is the study double blind? If yes then 1 point<BR/>Is the double blind method reported and is it appropriate? If yes then add 1 point, if not deduct 1<BR/>Are withdrawals and dropouts described? If yes add 1 point</P>
<P>For inclusion in this review trials had to achieve a minimum quality score of two out of the maximum of five (i.e., had to be of randomised and double blind design). 'Consensus' scores were agreed by the authors for each study, as follows:</P>
<P>Quality score of 5 (maximum): <LINK REF="STD-Mora_x002d_Durban-1995" TYPE="STUDY">Mora-Durban 1995</LINK>
</P>
<P>Quality score of 4: <LINK REF="STD-Comeri-1985" TYPE="STUDY">Comeri 1985</LINK>; <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>
</P>
<P>Quality score of 3: <LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>; <LINK REF="STD-Miralles-1987" TYPE="STUDY">Miralles 1987</LINK>; <LINK REF="STD-Muriel-1993" TYPE="STUDY">Muriel 1993</LINK>; <LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>; <LINK REF="STD-Sanahuja-1990" TYPE="STUDY">Sanahuja 1990</LINK>; <LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>
</P>
<P>Quality score of 2: <LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Lloret-1986" TYPE="STUDY">Lloret 1986</LINK>
</P>
<P>These scores were not used to weight the results in any way.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-04-20 16:05:32 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies with 1053 patients in total, 550 on dipyrone, met the inclusion criteria and contributed to the analysis.</P>
<P>Studies assessed intramuscular and/or intravenous dipyrone, given alone or in combination with other treatments. Direct comparison of intramuscular and intravenous administration was conducted in one trial (<LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>), although patients given intramuscular treatments had to be excluded from the analysis because no uncontaminated single dose data were provided. None of the included studies used oral administration; all used an active control and none used placebo.</P>
<SUBSECTION>
<HEADING LEVEL="3">Intramuscular dipyrone</HEADING>
<P>Five trials assessed intramuscular dipyrone, given alone or in combination with other treatments, and provided uncontaminated single dose data (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Miralles-1987" TYPE="STUDY">Miralles 1987</LINK>, <LINK REF="STD-Mora_x002d_Durban-1992" TYPE="STUDY">Mora-Durban 1992</LINK>; <LINK REF="STD-Mora_x002d_Durban-1995" TYPE="STUDY">Mora-Durban 1995</LINK>; <LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>). Intramuscular treatments compared in the trials were:</P>
<UL>
<LI>dipyrone 1 g or 2 g given alone</LI>
<LI>dipyrone 2 g plus hyoscine 20 mg</LI>
<LI>diclofenac 75 mg</LI>
<LI>pethidine 100 mg</LI>
<LI>flurbiprofen 150 mg</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intravenous dipyrone</HEADING>
<P>Seven trials assessed intravenous dipyrone, given alone or in combination with other treatments, and provided uncontaminated single dose data (<LINK REF="STD-Comeri-1985" TYPE="STUDY">Comeri 1985</LINK>; <LINK REF="STD-Lloret-1986" TYPE="STUDY">Lloret 1986</LINK>; <LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>; <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>; <LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>; <LINK REF="STD-Sanahuja-1990" TYPE="STUDY">Sanahuja 1990</LINK>; <LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>). Intravenous treatments compared in the trials were</P>
<UL>
<LI>dipyrone 1 g, 2 g or 2.5 g given alone</LI>
<LI>dipyrone 2.5 g plus hyoscine 20 mg</LI>
<LI>dipyrone 1 g plus pitofenon 0.4 mg plus fenpiverine 0.04 mg</LI>
<LI>dipyrone 2.5 g plus pitofenon 10 mg plus fenpipramide bromethylate 0.1 mg (Baralgin)</LI>
<LI>butylscopalmine 20 mg</LI>
<LI>diclofenac 75 mg</LI>
<LI>hyoscine 20 mg</LI>
<LI>ketorolac 30 mg</LI>
<LI>tramadol 100 mg</LI>
</UL>
<P>Other comparators were intramuscular diclofenac 75 mg and sublingual nifedipine 10 mg.</P>
<P>A number of studies allowed patients to receive a second dose of study medication within the observation period (e.g. after 30 minutes if adequate pain relief was not achieved). From these studies we extracted single dose information collected before the time at which the second dose was allowed. The following analyses were conducted using the uncontaminated, single dose data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Efficacy</HEADING>
<P>So little patient information was provided in the included studies that it would have been inappropriate to derive estimates of relative risk, numbers-needed-to-treat or confidence intervals around efficacy estimates. Results of the efficacy analysis are presented as weighted mean percent of patients achieving at least 50% pain relief (=50%maxTOTPAR) with the range of values from trials contributing to the analysis. These data are shown in Table 1 and Figures 1-3 which are available through the internet at: http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html</P>
<P>1. INTRAMUSCULAR DIPYRONE</P>
<UL>
<LI>Dipyrone 1 g</LI>
</UL>
<P>One trial presented information for intramuscular dipyrone 1 g compared with diclofenac 75 mg or pethidine 100 mg over 30 minutes (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>). The response rate (proportion of patients with at least 50% pain relief) with dipyrone 1 g was 62% (72/116 patients), with pethidine 100 mg it was 68% (80/118 patients) and with diclofenac 75 mg it was 68% (78/116 patients).</P>
<UL>
<LI>Dipyrone 2 g</LI>
</UL>
<P>Two trials presented information for intramuscular dipyrone 2 g compared with diclofenac 75 mg 30 minutes (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Miralles-1987" TYPE="STUDY">Miralles 1987</LINK>). One also used pethidine as an active comparator (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>). The data were homogeneous (P = 0.3). The response rate (proportion of patients with at least 50% pain relief) with intramuscular dipyrone 2 g was 65% in both trials (80/124 patients). With diclofenac 75 mg the response rates were 68% and 82% (mean 70%; 100/143 patients).</P>
<UL>
<LI>Dipyrone 2 g plus hyoscine 20 mg</LI>
</UL>
<P>Two trials presented information for intramuscular dipyrone 2 g plus hyoscine 20 mg compared with flurbiprofen 150 mg over 20 minutes (<LINK REF="STD-Mora_x002d_Durban-1992" TYPE="STUDY">Mora-Durban 1992</LINK>; <LINK REF="STD-Mora_x002d_Durban-1995" TYPE="STUDY">Mora-Durban 1995</LINK>). The data were homogeneous (P = 0.3). The response rates (proportion of patients with at least 50% pain relief) with intramuscular dipyrone 2 g plus hyoscine 20 mg were 28% and 48% (mean 42%; 37/90 patients). The response rates with flurbiprofen 150 mg were 36% and 69% (mean 60%; 53/89 patients).</P>
<UL>
<LI>Combination drug</LI>
</UL>
<P>One study (<LINK REF="STD-Comeri-1985" TYPE="STUDY">Comeri 1985</LINK>) assessed an intramuscular injection of a combination drug made up of dipyrone 1 g plus pitofenon 0.4 mg plus fenpiverine 0.04 mg. The study presented information for the combination drug compared with diclofenac 75 mg over five hours and presented the proportion of patients with at least 50% pain relief at one hour. The response rate with the combination drug was 56% (28/50 patients) and that with diclofenac 75 mg was 79% (38/48 patients).</P>
<P>2. INTRAVENOUS DIPYRONE</P>
<UL>
<LI>Dipyrone 1 g</LI>
</UL>
<P>
<BR/>One trial presented information for intravenous dipyrone 1 g compared with intravenous hyoscine 20 mg over 30 minutes (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>). The response rate with intravenous dipyrone 1 g was 70% (16/23 patients) and with hyoscine 20 mg it was 26% (6/23 patients).</P>
<P>One trial presented information for intravenous dipyrone 1 g compared with intravenous diclofenac 75 mg over six hours (<LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>). The response rate with intravenous dipyrone 1 g was 73% (23/32 patients) and with control it was 82% (18/22 patients).</P>
<UL>
<LI>Dipyrone 2 / 2.5 g</LI>
</UL>
<P>One trial presented information for intravenous dipyrone 2.5 g compared with intravenous hyoscine 20 mg over 30 minutes (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>). The response rate with intravenous dipyrone 2.5 was 91% (23/25 patients) and with hyoscine 20 mg it was 26% (6/23 patients).</P>
<P>One trial presented information for intravenous dipyrone 2.5 g compared with intravenous tramadol 100 mg or butylscopalamine 20 mg over two hours (<LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>). The response rate with intravenous dipyrone 2.5 g was 88% (32/36 patients), with tramadol 100 mg it was 67% (23/35 patients) and with butylscopalamine 20 mg it was 65% (21/33 patients).</P>
<P>One trial presented information for intravenous dipyrone 2 g compared with diclofenac 75 mg over six hours (<LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>). The response rate with intravenous dipyrone 2 g (27/30 patients) was 89%. The response rate with control (18/22 patients) was 82%.</P>
<UL>
<LI>Dipyrone 2.5 g plus hyoscine 20 mg</LI>
</UL>
<P>One trial presented information for intravenous dipyrone 2.5 g plus hyoscine 20 mg compared with intravenous hyoscine 20 mg over 30 minutes (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>). The response rate with intravenous dipyrone 2.5 g plus hyoscine 20 mg was 85% (21/25 patients) and with hyoscine 20 mg it was 26% (6/23 patients).</P>
<P>One trial presented information for intravenous dipyrone 2.5 g plus hyoscine 20 mg compared with intravenous ketorolac 30 mg over one hour (<LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>). The response rate with intravenous dipyrone 2.5 g plus hyoscine 20 mg was 88% (22/25 patients) and with ketorolac 30 mg it was 88% (17/20 patients).</P>
<UL>
<LI>Combination drug</LI>
</UL>
<P>Two studies assessed an intravenous injection of a combination drug made up of dipyrone 2.5 g plus pitofenon 10 mg plus fenipramide bromethylate 0.1 mg (brand name Baralgin) compared with intramuscular diclofenac 75 mg or sublingual nifedipine 10 mg over 15-30 minutes (<LINK REF="STD-Sanahuja-1990" TYPE="STUDY">Sanahuja 1990</LINK>; <LINK REF="STD-Lloret-1986" TYPE="STUDY">Lloret 1986</LINK>). Uncontaminated single dose data was extracted over 15 minutes. The data were heterogeneous (P = 0.02). The mean response rate with intravenous Baralgin (30/46 patients) was 63% (58% and 67%), with nifedipine 10 mg it was 31% (8/25 patients) and with diclofenac 75 mg it was 47% (14/29 patients) over 15 minutes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>(see Table at <A HREF="http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html">www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html</A>)</P>
<P>Information on adverse effects from five trials could not be used because the data had been contaminated with further doses of analgesic. Six trials presented uncontaminated, single dose adverse effect information (<LINK REF="STD-Comeri-1985" TYPE="STUDY">Comeri 1985</LINK>; <LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>; <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>; <LINK REF="STD-Miralles-1987" TYPE="STUDY">Miralles 1987</LINK>; <LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>; <LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>). Two of these studies stated that no patients reported adverse effects (<LINK REF="STD-Comeri-1985" TYPE="STUDY">Comeri 1985</LINK>; <LINK REF="STD-Miralles-1987" TYPE="STUDY">Miralles 1987</LINK>). Adverse effects were reported in four trials (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>; <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>; <LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>; <LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Single dose data</HEADING>
<UL>
<LI>Two trials reported numeric information for particular adverse effects but did not mention the total number of patients with adverse effects (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>; <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>). The severity of the reported adverse effects was not mentioned in the study by <LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>, and that by <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK> stated that none of the adverse effects was clinically severe. The most frequently reported adverse effects were somnolence and dry mouth in both trials, but pain at the injection site occurred frequently in the study by <LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>.</LI>
<LI>Somnolence was reported by 5/23 (22%) patients with intravenous dipyrone 1 g, 6/25 (24%) patients with dipyrone 2.5 g, 23/50 (46%) patients with dipyrone 2.5 g plus hyoscine 20 mg, 6/23 (26%) with hyoscine 20 mg and 7/20 (35%) patients with ketorolac 30 mg</LI>
<LI>Dry mouth was reported by 5/23 (22%) patients with intravenous dipyrone 1 g, 7/25 (28%) patients with dipyrone 2.5 g, 33/50 patients (66%) with dipyrone 2.5 g plus hyoscine 20 mg, 11/23 (48%) patients with hyoscine 20 mg and 11/20 (55%) patients with ketorolac 30 mg.</LI>
<LI>Pain at the injection site was reported by 3/23 (13%) patients with dipyrone 1 g, 15/25 (60%) patients with dipyrone 2.5 g, 11/25 (44%) patients with dipyrone 2.5 g plus hyoscine 20 mg and 1/23 (4%) patients with hyoscine 20 mg. Pain at the injection site was reported to have resolved within a few minutes and not to have caused thrombophlebitis.</LI>
</UL>
<P>The other two studies (<LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>; <LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>) provided insufficient information to analyse the adverse effects:</P>
<P>
<LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>
<BR/>Single dose adverse effect information was available for intravenous dipyrone 1 g, dipyrone 2.5 g and diclofenac 75 mg over six hours. Information for the intramuscular treatments was contaminated because patients were given a second dose of analgesic. The number of patients reporting adverse effects with the study treatments was not provided. The most frequently reported adverse effects were:</P>
<UL>
<LI>drowsiness with intravenous dipyrone (1 g or 2.5 g)</LI>
<LI>dry mouth and hypotension with diclofenac 75 mg</LI>
<LI>severe drowsiness or vomiting with intravenous diclofenac 75 mg (reported by two (2/22; 9%) patients)</LI>
</UL>
<P>
<LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>
<BR/>Single dose information was available for intravenous dipyrone 2.5 g and tramadol 100 mg over two hours. One (1/36; 28%) patient reported adverse effects with dipyrone 2.5 g: moderate lightheadedness, nausea and vomiting. Four (4/35; 29%) patients reported adverse effects with tramadol 100 mg: two reported dizziness, one reported nausea and one reported blurred vision.</P>
<P>The 'Characteristics of included studies' table provides details of adverse events reported with multiple (contaminated) doses of study treatments in the studies that provided no single dose data.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-04-20 16:05:54 +0100" MODIFIED_BY="[Empty name]">
<P>Despite rigorous searching, checking bibliographies of retrieved articles, contact with pharmaceutical companies and authors only 11 studies could be included in this systematic review. All used an active treatment as a control, and none used placebo. Since all trials were randomised and double blind the potential for selection or observer bias should have been minimised. Trials were generally of good quality (median quality score 3). Use of rescue medication was well described in the trials but descriptions of study withdrawals were poor.</P>
<P>The included trials were small, assessed a number of different doses of dipyrone (alone or in combination with other treatments), and different routes of administration (intramuscular or intravenous). Few patient data were available for analysis and most analyses were based on the results of single, small trials. The estimates of analgesic efficacy generated were not robust and statistical significance of results was not tested. Figures 1 and 2 available at the website: http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html, show the percent of patients with at least 50% pain relief for the intramuscular and intravenous drugs tested, with the largest points representing the largest analyses.</P>
<P>The duration of assessment and outcome data collection in the trials were considered important. This analysis was hindered by contamination of single dose information in some trials as a result of the administration of a second dose (or rescue medication) before the end of the observation period. For trials in which patients remedicated within the observation period, information was extracted for the time period before rescue medication (or a second dose) was allowed. Calculations were conducted using the evaluable single dose efficacy information at 15-30 minutes, 1-2 hours or six hours. From the data available similar proportions of patients achieved at least 50% pain relief at 15-30 minutes, 1-2 hours or six hours (see Figure 3 at the website http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html), although the comparability of information over the different time points is uncertain.</P>
<P>Active comparators in trials of intramuscular dipyrone were diclofenac, flurbiprofen, pethidine and indomethacin. Limited information showed similar efficacy between intramuscular dipyrone and comparator treatments (see Table 1 at the website <A HREF="http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html">http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html</A>), but with slightly lower response rates for dipyrone in direct comparisons with diclofenac. There was no evidence of a dose response for efficacy with increasing dose of intramuscular dipyrone (1 g or 2 g) using indirect or direct comparisons.</P>
<P>For intravenous dipyrone there was some evidence of a dose-response for efficacy (see Table 1 at the website <A HREF="http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html">http://www.jr2.ox.ac.uk/Bandolier/painres/diprenco/diprenco.html</A>). It was also more effective than intravenous hyoscine 20 mg, tramadol 100 mg, butylscopalamine 20 mg, sublingual nifedipine 10 mg, intramuscular diclofenac 75 mg and of similar efficacy to intravenous ketorolac 30 mg.</P>
<P>There were no direct comparisons of intravenous dipyrone against intramuscular dipyrone, although indirect comparisons showed higher response rates with the intravenous drug. Real differences between intravenous and intramuscular dose cannot be substantiated because of the paucity of information.</P>
<P>The addition of spasmolytic agents (e.g. hyoscine) to dipyrone did not appear to improve its analgesic efficacy.</P>
<P>Information on adverse effects could not be pooled in a meta-analysis. In the majority of studies the information was contaminated because further doses of study medication were administered to patients within the observation period. In this systematic review, the objective was to establish the adverse effects caused by a single dose of dipyrone in acute renal colic pain. Combining information from these studies would have confounded the information gathered on adverse effects. Uncontaminated, single dose adverse effect information could be extracted from only four studies (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>; <LINK REF="STD-Martin-Carrasco-1993" TYPE="STUDY">Martin Carrasco 1993</LINK>; <LINK REF="STD-Muriel-Villoria-1995" TYPE="STUDY">Muriel Villoria 1995</LINK>; <LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>). These assessed intravenous dipyrone (with or without hyoscine 20 mg) compared with an active control drug. None of the adverse effects reported with dipyrone was severe in nature, although one patient reported moderate lightheadedness with dipyrone 2.5 g in one trial (<LINK REF="STD-Stankov-1994" TYPE="STUDY">Stankov 1994</LINK>). The most commonly reported adverse effects with dipyrone were dry mouth and somnolence (drowsiness). Pain at the injection site occurred with single doses of all study treatments in one trial (<LINK REF="STD-Lloret-1987" TYPE="STUDY">Lloret 1987</LINK>). With multiple doses, pain at the injection site with dipyrone was common (<LINK REF="STD-Sanahuja-1990" TYPE="STUDY">Sanahuja 1990</LINK>; <LINK REF="STD-Mora_x002d_Durban-1995" TYPE="STUDY">Mora-Durban 1995</LINK>).</P>
<P>The trials indicate that dipyrone could be of similar efficacy to other tested analgesics, possibly with the exception of intramuscular diclofenac, in the treatment of moderate to severe renal colic pain in adults. Cautious interpretation of the results is needed because most analyses were based on the results of single, small trials.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The results obtained in this analysis were not robust, because few patients were included in the analyses for the different doses of dipyrone and the different routes of administration. Intravenous dipyrone appears to be an effective analgesic for treating renal colic pain.</P>
<P>Pain at the injection site occurred frequently in studies which assessed multiple doses of dipyrone, and was also reported in one single dose study.</P>
<P>There was insufficient information of adequate quality for any safety analyses to be conducted. Dipyrone is known to cause blood dyscrasias such as agranulocytosis (an adverse effect which can occur with short-term treatment) but there was no mention of blood dyscrasias in these trials. There is a wealth of literature on agranulocytosis: the most recent, large, international study found vastly differing rates of agranulocytosis in the 11 countries where information was collected (<LINK REF="REF-IAAA-Study-1986" TYPE="REFERENCE">IAAA Study 1986</LINK>). There are a number of published criticisms of this study (<LINK REF="REF-Kramer-1988" TYPE="REFERENCE">Kramer 1988</LINK>). None of these criticisms mentions the importance of size (of the population studied and the analyses) for detecting true incidence rates for rare events. Size is an important issue of study validity (<LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>). Recent reports from Sweden have suggested a rate of one case of agranulocytosis in 1700 prescriptions. This rate was based on six cases in 10,000 prescriptions. Information is available on the Swedish website (http://www.mpa.se/biverkningar/biv99/novalgin.html). In the absence of other robust information, the Swedish data is probably the most reliable on which to base decisions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The risk of agranulocytosis needs to be quantified using adequately powered studies of good methodological design. Methodologically rigorous studies would be required to establish the benefit/risk trade-off for dipyrone, particularly if the risk of rare adverse events was to be established. Such studies would need to be large, of adequate duration, provide clear definitions of outcomes and independent verification of cases, and provide information on exposure to treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The following helped retrieve specific papers: Joan-Ramon Laporte, University of Barcelona (Spain); José Gíl, Hospital General Universitario of Murcia (Spain); Luis Miguel Torres Hospital Universitario. Puerta del Mar Cádiz (Spain); Jordi Camí Institut Universitat Pompeu Fabra, Barcelona (Spain); Vladimir Stoukov, Centre for Evidence-based Medicine (Moscow); Medical Information Unit, Aventis Pharma (UK); Pablo Ortiz, Boehringer Ingelheim, Madrid (Spain). Anna Oldman kindly translated German reports. Nicola Thornton transferred text and data for this review into RevMan.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Fuensanta Meseguer was supported by an unrestricted, educational grant from Boehringer Ingelheim Laboratories, Madrid, Spain. The remaining authors had no conflicts of interest. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-21 12:10:59 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnau-1991" NAME="Arnau 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnau JM</AU>
<TI>Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic</TI>
<SO>Eur J Clin Pharmacol</SO>
<YR>1991</YR>
<VL>40</VL>
<PG>543-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356412"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356411"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comeri-1985" NAME="Comeri 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comeri G, Radice GP, Duvia R, Manganini V, Monza G</AU>
<TO>Efficacia e tollerabilità degli antifiammatori non steroidei nella colica ureterale</TO>
<SO>Urologia</SO>
<YR>1985</YR>
<VL>52</VL>
<NO>2</NO>
<PG>268-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356414"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356413"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloret-1986" NAME="Lloret 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloret J, Vila A, Puig X, Monmany J, Munoz J, More J</AU>
<TI>Nifedipine in the treatment of renal colic</TI>
<SO>Methods Find Exp Clin Pharmacol</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>9</NO>
<PG>575-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356416"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356415"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloret-1987" NAME="Lloret 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloret J, Munoz J, Monmany J, Puig X, Bonastre M, Brau J et al</AU>
<TI>Treatment of renal colic with dipyrone. A double-blind comparison trial with hyoscine alone or combined with dipyrone</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1987</YR>
<VL>42</VL>
<NO>6</NO>
<PG>1119-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356418"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356417"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-Carrasco-1993" NAME="Martin Carrasco 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin Carrasco C, Rodriguez Vazquez M, Palacios Garcia R</AU>
<TI>A double-blind study of the analgesic efficacy in kidney colic of the combination of dipyrone and spasmolytic with ketorolac trometamol</TI>
<SO>Arch Esp Urol</SO>
<YR>1993</YR>
<VL>46</VL>
<NO>9</NO>
<PG>763-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356420"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356419"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miralles-1987" NAME="Miralles 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miralles R, Cami J, Gutierrez J, Torne J, Garces JM, Badenas JM</AU>
<TI>Diclofenac versus dipyrone in acute renal colic: a double-blind controlled trial</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>33</VL>
<NO>5</NO>
<PG>527-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356422"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356421"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mora_x002d_Durban-1992" NAME="Mora-Durban 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mora-Durban MJ, Extramiana J, Navarro FJ et al</AU>
<TI>Flurbiprofen: Alternative treatment in renal colic pain</TI>
<SO>Arch Esp de Urol</SO>
<YR>1992</YR>
<VL>45</VL>
<NO>8</NO>
<PG>773-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356424"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356423"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mora_x002d_Durban-1995" NAME="Mora-Durban 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mora-Durban MJ, Extramiana-Cameno J, Arrizabalaga-Moreno M et al</AU>
<TI>Flurbiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic</TI>
<SO>Arch Esp Urol</SO>
<YR>1995</YR>
<VL>48</VL>
<PG>867-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356426"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356425"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muriel-Villoria-1995" NAME="Muriel Villoria 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muriel Villoria C, Zungri Telo E, Diaz Curiel M et al</AU>
<TI>Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>48</VL>
<NO>2</NO>
<PG>103-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356428"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanahuja-1990" NAME="Sanahuja 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanahuja J, Corbera G, Garau J, Pla R, Carre MC</AU>
<TI>Intramuscular diclofenac sodium versus intravenous Baralgin in the treatment of renal colic</TI>
<SO>Dicp Ann Pharmacother</SO>
<YR>1990</YR>
<VL>24</VL>
<NO>4</NO>
<PG>361-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356430"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356429"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stankov-1994" NAME="Stankov 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stankov G, Schmieder G, Zerle G, Schinzel S, Brune K</AU>
<TI>Double-blind study with dipyrone versus tramadol and butylscopolamine in acute renal colic pain</TI>
<SO>World J Urol</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>3</NO>
<PG>155-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356432"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356431"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arico-1983" NAME="Arico 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arico F</AU>
<TO>Tratamento da cólica nefrética com a associaçáo de dipirona com brometo de fenpiverínio</TO>
<SO>F Med (Br)</SO>
<YR>1983</YR>
<VL>86</VL>
<NO>3</NO>
<PG>181-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356434"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356433"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benyajati-1986" NAME="Benyajati 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benyajati C</AU>
<TI>Comparative study of Baralgan and hyoscine-N-methyl bromide in the treatment of intestinal and renal colicy pain</TI>
<SO>J Med Assoc Thai</SO>
<YR>1986</YR>
<VL>69</VL>
<NO>10</NO>
<PG>569-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356436"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356435"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borelli-1984" NAME="Borelli 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borelli A, Roversi P, Palmieri B, Saponati G, Gallo M.</AU>
<TI>Medical therapy of ureteral colic. A comparative clinical study of 3 spasmolytics, 1 of which is combined with an analgesic</TI>
<SO>Minerva Urol Nefrol</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>3</NO>
<PG>253-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356438"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356437"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campero-1993" NAME="Campero 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campero J M, Susaeta R, Verbal X, Roman M, Garcia M</AU>
<TI>Treatment of renal colic</TI>
<TO>Tratamiento del colico renal</TO>
<SO>Bol Hosp San Juan de Dios</SO>
<YR>1993</YR>
<VL>40</VL>
<NO>4</NO>
<PG>185-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356440"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356439"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Sherif-1990" NAME="El Sherif 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Sherif AE, Foda R, Norlen LJ, Yahia H</AU>
<TI>Treatment of renal colic by prostaglandin synthetase inhibitors and avafortan (analgesic antispasmodic)</TI>
<SO>Br J Urol</SO>
<YR>1990</YR>
<VL>66</VL>
<PG>602-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356442"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356441"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galassi-1983" NAME="Galassi 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galassi P, Vicentini C, Scapellato F, Laurenti C</AU>
<TI>Use of indomethacin and metamizole administered intravenously in renal colic. Comparative study</TI>
<SO>Minerva Urol</SO>
<YR>1983</YR>
<VL>35</VL>
<NO>4</NO>
<PG>295-300</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356444"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356443"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Indudhara-1990" NAME="Indudhara 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Indudhara R, Vaidyanathan S, Sankaranarayanan A</AU>
<TI>Oral diclofenac sodium in the treatment of acute renal colic. A prospective randomized study</TI>
<SO>Clin Trials J</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>295-300</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356446"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356445"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalil-1982" NAME="Kalil 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalil M</AU>
<TI>Effect of the combination of 2.5 g of dipyrone with 0.1 mg of fenpiverinium bromide in the treatment of renal colic</TI>
<SO>Folha Med</SO>
<YR>1982</YR>
<VL>85</VL>
<NO>5-6</NO>
<PG>959-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356448"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356447"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehtonen-1983" NAME="Lehtonen 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehtonen T, Kellokumpu I, Permi J, Sarsila O</AU>
<TI>Intravenous indomethacin in the treatment of ureteric colic. A clinical multicentre study with pethidine and metamizol as the control preparations</TI>
<SO>Ann Clin Res</SO>
<YR>1983</YR>
<VL>15</VL>
<NO>5-6</NO>
<PG>197-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356450"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356449"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marthak-1991" NAME="Marthak 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marthak KV, Gokarn AM, Rao AV et al</AU>
<TI>A multi-centre comparative study of diclofenac sodium and a dipyrone/spasmolytic combination, and a single-centre comparative study of diclofenac sodium and pethidine in renal colic patients in India</TI>
<SO>Curr Med Res Opin</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>6</NO>
<PG>366-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356452"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356451"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muriel-1993" NAME="Muriel 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muriel C, Ortiz P, Mella G et al</AU>
<TI>Efficacy of two different intramuscular doses of dipyrone in acute renal colic</TI>
<SO>Methods Find Exp Clin Pharmacol</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>7</NO>
<PG>465-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356454"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356453"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardo-1984" NAME="Pardo 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardo A, Iriarte JL, de Paolis C</AU>
<TI>Comparison of the effects of ceruletide with respect to dipyrone and to a single infusion of physiologic serum in patients with pain due to nephritic colic</TI>
<TO>Comparacion de la actividad del Ceruletide respecto a la Dipirona y a la sola infusion de suero fisiologico en pacientes con dolor por colico nefritico</TO>
<SO>Arch Esp Urol</SO>
<YR>1984</YR>
<VL>37</VL>
<NO>2</NO>
<PG>94-100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356456"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356455"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pourrat-1984" NAME="Pourrat 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pourrat JP</AU>
<TI>Treatment of renal colic with ketoprofen</TI>
<SO>Presse Med</SO>
<YR>1984</YR>
<VL>13</VL>
<PG>2125-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356458"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Primus-1989" NAME="Primus 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Primus G, Pummer K, Vucsina F, Meindl N</AU>
<TI>Tramadol versus metimazole in alleviating pain in ureteral colic</TI>
<SO>Urologe A</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>2</NO>
<PG>103-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3356460"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3356459"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-28 14:32:00 +0100" MODIFIED_BY="Sheena Derry">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-28 14:32:00 +0100" MODIFIED_BY="Sheena Derry">
<REFERENCE ID="REF-Arrellano-1990" NAME="Arrellano 1990" TYPE="JOURNAL_ARTICLE">
<AU>Arrellano F, Sacristán JA</AU>
<TI>Metamizol: reassessment of its therapeutic role</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1990</YR>
<VL>38</VL>
<PG>617-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besson-1987" NAME="Besson 1987" TYPE="JOURNAL_ARTICLE">
<AU>Besson JM, Choauch A</AU>
<TI>Peripheral and spinal mechanisms of nociception</TI>
<SO>Physiol Rev</SO>
<YR>1987</YR>
<VL>67</VL>
<PG>67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1997" NAME="Collins 1997" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Moore RA, McQuay HJ</AU>
<TI>The visual analogue pain intensity scale: what is moderate pain in millimetres?</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>72</VL>
<PG>95-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2001" NAME="Collins 2001" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Edwards, JE, Moore, RA, Smith LA, McQuay HJ</AU>
<TI>Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>91</VL>
<PG>189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1991" NAME="Cooper 1991" TYPE="JOURNAL_ARTICLE">
<AU>Cooper SA</AU>
<TI>Single-dose analgesic studies: the upside and downside of assay sensitivity. In: Max MB, Portenoy RK, Laska EM Eds.</TI>
<SO>The design of analgesic clinical trials - Advances in Pain Research and Therapy</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>117-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESPSCP-1991" NAME="ESPSCP 1991" TYPE="JOURNAL_ARTICLE">
<AU>Collaborative Group of the Spanish Society of Clinical Pharmacology</AU>
<TI>Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic</TI>
<SO>Eur J Clin Pharmcol</SO>
<YR>1991</YR>
<VL>40</VL>
<PG>543-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-1992" NAME="Foster 1992" TYPE="JOURNAL_ARTICLE">
<AU>Foster C, Magerl W, Beck A, Gersslinger G, Gall T, Brune K, Handwerker HO</AU>
<TI>Differential effects of dipyrone, ibuprofen and paracetamol on experimentally-induced pain in man</TI>
<SO>Agents and Actions</SO>
<YR>1992</YR>
<VL>35</VL>
<PG>112-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IAAA-Study-1986" NAME="IAAA Study 1986" TYPE="JOURNAL_ARTICLE">
<AU>International Agranulocytosis and Aplastic Anemia Study</AU>
<TI>Risks of Agranulocytosis and Aplastic Anemia - A first report of their relation to drug use with special reference to anaglesics</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>13</NO>
<PG>1749-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996a" NAME="Jadad 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Carroll D, Moore A, McQuay H</AU>
<TI>Developing a database of published reports of randomised clinical trials in pain research</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996b" NAME="Jadad 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kramer-1988" NAME="Kramer 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS</AU>
<TI>The International Agranulocytosis and Aplastic Anemia Study (IAAAS)</TI>
<SO>J Clin Epidemiol</SO>
<YR>1988</YR>
<VL>41</VL>
<NO>6</NO>
<PG>613-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1996" NAME="Moore 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997a" NAME="Moore 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Verification from independent data</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997b" NAME="Moore 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, Moore O, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Use of pain intensity and visual analogue scales</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<PG>311-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1998" NAME="Moore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ</AU>
<TI>Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>3</NO>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quilez-1984" NAME="Quilez 1984" TYPE="JOURNAL_ARTICLE">
<AU>Quilez C, Perez Mateo M, Hernandez P, Rubio I</AU>
<TO>Utilidad de un antiinflamatorio no esteriodeo, diclofenac sodico, en el tratamiento del colico nefritico. Estudio compartivo con un espasmolitico y un analgesico opiaceo</TO>
<SO>Med Clin</SO>
<YR>1984</YR>
<VL>82</VL>
<PG>754-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1993" NAME="Reynolds 1993" TYPE="BOOK">
<AU>Reynolds JEF</AU>
<SO>Martindale: the extra pharmacopoeia 292-314</SO>
<YR>1993</YR>
<VL>292-314</VL>
<EN>30</EN>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schaible-1985" NAME="Schaible 1985" TYPE="JOURNAL_ARTICLE">
<AU>Schaible HG, Schmidt RF</AU>
<TI>Effects of an experimental arthritis on the sensory properties of fine articular afferents units. J Neurophysiol 1985; 54:1109</TI>
<SO>J Neurophysiol</SO>
<YR>1985</YR>
<VL>54</VL>
<PG>1109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Victorov-1978" NAME="Victorov 1978" TYPE="CONFERENCE_PROC">
<AU>Victorov I</AU>
<TI>A clinical study of dipyrone (Analgin) in urologic patients</TI>
<SO>The proceedings of the dipyrone symposium, Moscow 1978</SO>
<YR>1980</YR>
<PB>Schattauer Verlag</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-04-20 16:09:42 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-04-20 16:09:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-04-20 16:06:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnau-1991">
<CHAR_METHODS>
<P>Randomised, double blind</P>
<P>No placebo group </P>
<P>Baseline PI = moderate or severe pain (80mm in VAS 0-100)<BR/>Self assessment at t = 0, 15, 30 min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-20 16:06:15 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with diagnosed renal colic pain<BR/>N=451</P>
<P>Dipyrone 1 g , n=116<BR/>Dipyrone 2 g, n=101<BR/>Diclofenac 75 mg, n=116<BR/>Pethidine 100 mg, n=118<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 1 g <BR/>Dipyrone 2 g <BR/>Diclofenac 75 mg<BR/>Pethidine 100 mg</P>
<P>Single IM dose, 30 min.</P>
<P>If pain after 30 min not decreased at least 25%, pethidine 100 mg was given as rescue<BR/>medication.<BR/>20% per group remedicated.<BR/>43% (193/451) patients took rescue medication<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>PI=VAS 0-100 mm, (0=no pain; 100=excruciating pain)<BR/>PR=verbal scale nonstandard (0-3)</P>
<P>30 min SPID:<BR/>Dipyrone 2 g=19.87<BR/>Dipyrone 1g=20<BR/>Diclofenac 75 mg=22.75<BR/>Pethidine 100 mg=21.75</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>AE information is 'number of events' not 'number of patients'.</P>
<P>Multiple dose AEs:<BR/>Number of AEs per group:<BR/>Warm feeling &amp; metalic taste, dryness of the mouth, sweating: dipyrone 1g (10); dipyrone 2g (12); diclofenac 75 mg (7); pethidine 100 mg (23).<BR/>Nausea: dipyrone 1g (20);</P>
<P>QS=2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:06:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comeri-1985">
<CHAR_METHODS>
<P>Randomised, double blind, active control,</P>
<P>No placebo group</P>
<P>Baseline PI = moderate or severe pain (82.5 mm on a 100 mm VAS)</P>
<P>Self assessment at t = 0, 0.5, 1 hr</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=148</P>
<P>Dipyrone 1 g + pitofenon 0.4 mg + fenpiverine 0.04 mg, n=50</P>
<P>Diclofenac 75 mg, n=48</P>
<P>Indomethacin 50 mg, n= 50</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 1 g + pitofenon 0.4 mg + fenpiverine 0.04 mg </P>
<P>Diclofenac 75 mg</P>
<P>Indomethacin 50 mg</P>
<P>Single IM dose, 1 hr</P>
<P>If the PI had not decreased by 50% of the initial value at 60 mins after the first dose, the patient received a second injection of the same drug in a double blind manner.<BR/>Any patient not experiencing a decrease of PI after the second dose was removed from the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:06:38 +0100" MODIFIED_BY="[Empty name]">
<P>PI (VAS 0-100 mm)</P>
<P>PR &gt; 50% at<BR/>30mins:<BR/>Dipyrone=28/50<BR/>Diclofencac=38/48 Indomethacin = 34/50</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No AEs were reported by any patient</P>
<P>Single dose AEs:<BR/>15 patients dropped out: diclofenac<BR/> (3), indomethacin (6), dipyrone (6)</P>
<P>QS=4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:06:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lloret-1986">
<CHAR_METHODS MODIFIED="2011-04-20 16:06:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, single IV &amp; sublingual dose,<BR/>2 hrs</P>
<P>No placebo group</P>
<P>Baseline PI=moderate or severe pain</P>
<P>Self assessment at t=0, 10, 20, 30, 60, 120 min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=43</P>
<P>Intravenous dipyrone 2.5 g + pitofenone 10 mg + fenpipramide bromomethylate 0.1mg (Baralgin), n=18 </P>
<P>Sublingual nifedipine 10 mg, n=25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous dipyrone 2.5 g + pitofenone 10 mg + fenpipramide bromomethylate 0.1mg (Baralgin)</P>
<P>Sublingual nifedipine 10 mg </P>
<P>Remedication was allowed 15 min after the initial dose if a clear improvement was not observed.<BR/>After another 15 min a third dose was given (treatment regimes were swapped so that a patient who received dipyrone at the start was given nifedipine, and vice versa</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:06:54 +0100" MODIFIED_BY="[Empty name]">
<P>PI: standard scale (0-3)</P>
<P>30 min data provided; up to 15 min uncontaminated single dose data.</P>
<P>15 min SPID:<BR/>Dipyrone=0.2785<BR/>Nifedipine=0.1749</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>AE information is 'number of events' not 'number of patients'.</P>
<P>Multiple dose AEs:<BR/>Number of AEs: nifedipine (1); dipyrone (15)</P>
<P>Warm feeling &amp; metalic taste, dry mouth, sweating: dipyrone (7).</P>
<P>Nausea: dipyrone (2); nifedipine (1).</P>
<P>Dizziness: dipyrone (1)</P>
<P>Somnolence:<BR/>dipyrone (1)</P>
<P>Headache: Dipyrone (1)<BR/>Pain at injection site - dipyrone (3)</P>
<P>QS=2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:07:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lloret-1987">
<CHAR_METHODS MODIFIED="2011-04-20 16:07:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind,</P>
<P>No placebo group</P>
<P>Baseline PI=moderate or severe pain &gt; 70 mm VAS</P>
<P>Self assessment at t=0, 10, 20, 30 min<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=96</P>
<P>Dipyrone 2.5 g, n=25</P>
<P>Diprone 2.5 g + hyoscine 20 mg, n=25</P>
<P>Dipyrone 1 g, n=23</P>
<P>Hyoscine 20 mg, n=23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 2.5 g</P>
<P>Diprone 2.5 g + hyoscine 20 mg,</P>
<P>Dipyrone 1 g</P>
<P>Hyoscine 20 mg </P>
<P>Single IV dose, 30 min</P>
<P>Rescue analgesic (100 mg pethidine IV) was allowed after 30 min if PR &lt;50%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>PI by patient: 100 mm VAS (0=no pain; 100=intolerable pain).</P>
<P>PI by observer : standard scale (0-3)</P>
<P>30 min SPID:<BR/>Dipyrone 2.5 g=28.49</P>
<P>Dipyrone 2.5 g + hyoscine=26.58</P>
<P>Dipyrone 1 g=22.49</P>
<P>Hyoscine 20 mg=8.98</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4 patients were excluded because of the lack of diagnostic criteria<BR/>or inappropiate recording of data</P>
<P>Single dose AEs:<BR/>AE information is 'number of events' not 'number of patients'.</P>
<P>Number of AEs:</P>
<P>Warm feeling &amp; metalic taste, dry mouth, sweating: dipyrone 2.5 g (7); dipyrone 2.5 g + hyoscine 20 mg (11); dipyrone 1 g (5); hyoscine 20 mg (11).</P>
<P>Gastric discomfort: dipyrone 2.5 g (6); dipyrone 2.5g + hyoscine 20 mg (4); dipyrone 1 g (3); hyoscine 20 mg (2).<BR/>Dizziness: dipyrone 2.5 g (3); dipyrone 2.5g + hyoscine 20 mg (4).<BR/>Somnolence: dipyrone 2.5 g (6); dipyrone 2.5 g + hyoscine 20 mg (9);<BR/>dipyrone 1 g (5); hyoscine 20 mg (6).<BR/>Headache: dipyrone 2.5 g + hyoscine 20 mg (1); dipyrone 1 g (1).<BR/>Local pain at injection site: dipyrone 2.5 g (15); dipyrone 2.5 mg + hyoscine 20 mg (11); dipyrone 1 g (3); hyoscine 20 mg (1)<BR/>Skin reactions: dipyrone 2.5 g + hyoscine 20 mg (1); dipyrone 1 g (1)</P>
<P>QS=3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:07:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin-Carrasco-1993">
<CHAR_METHODS>
<P>Randomised, double blind, </P>
<P>Baseline PI = moderate or severe pain (VAS &gt;60 mm)</P>
<P>Self assessment at t = 0, 30, 60 min<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=34</P>
<P>Dipyrone 2.5 g + hyoscine 20 mg, n=17</P>
<P>Ketoralac 30 mg, n=17</P>
<P>Patients who took rescue analgesia were excluded from the study</P>
<P>1 previously enrolled in the study<BR/>3 from ketorolac group <BR/>8 from dipyrone group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 2.5 g + hyoscine 20 mg, n=17<BR/>Ketoralac 30 mg, n=17</P>
<P>single IV dose, 1hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:07:44 +0100" MODIFIED_BY="[Empty name]">
<P>PI=100 mm VAS (0=no pain; 100=excruciating pain)<BR/>PR (5 point) nonstandard scale</P>
<P>1hr SPID:</P>
<P>Dipyrone 2.5 g + hyoscine 20 mg = 46.6</P>
<P>Ketorolac 30 mg=47.4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>AE information is 'number of events' not 'number of patients'.</P>
<P>Single dose AEs:<BR/>Number of AEs:</P>
<P>Warm feeling &amp; metalic taste, dry mouth, sweating: dipyrone 2.5 g + hyoscine 20 mg (22); ketoralac 30 mg (11).</P>
<P>Gastric discomfort: dipyrone 2.5 g + hyoscine 20 mg (2).<BR/>Nausea: dipyrone 2.5 g + hyoscine 20 mg (1).<BR/>Dizziness: Ketoralac 30 mg (1)<BR/>Somnolence: dipyrone 2.5 g + hyoscine 20 n=mg (14); ketoralac 30 mg (7).<BR/>Headache: ketoralac 30 mg (3).<BR/>Local pain at injection site: dipyrone 2.5 g + hyoscine 20 mg (1)</P>
<P>QS=4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:08:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miralles-1987">
<CHAR_METHODS MODIFIED="2011-04-20 16:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind.</P>
<P>No placebo group</P>
<P>Baseline PI=moderate or severe pain</P>
<P>Self assessment at t=0 and 30 min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=50</P>
<P>Dipyrone 2 g, n=23</P>
<P>Diclofenac 75 mg, n=27</P>
<P>12 patients were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 2 g Diclofenac 75 mg</P>
<P>Single IM dose, 30 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>PI=100 mm VAS (0=no pain; 100=unbearable pain)<BR/>PR=100 mm VAS, (0% to 100% improvement)<BR/>Improvement=&lt;50% reduction in pain within 30 min of drug administration.</P>
<P>Presented dichotomous data<BR/>( &gt; 50% improvement in PR) at 30 min<BR/>Dipyrone=15/23<BR/>Diclofenac=22/27</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>12 patients were excluded. </P>
<P>No adverse effects were reported.</P>
<P>QS=3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:08:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mora_x002d_Durban-1992">
<CHAR_METHODS>
<P>Randomised, double blind</P>
<P>No placebo group</P>
<P>Baseline PI = severe pain</P>
<P>Self assessment at t = 0, 10, 20, 30, 45, 60 min<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=51</P>
<P>Dipyrone 2 g + hyoscine 20 mg: n=26</P>
<P>Flurbiprofen 150 mg: n=25</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 2 g + hyoscine 20 mg</P>
<P>Flurbiprofen 150 mg</P>
<P>Single IM dose, 1 hr</P>
<P>Rescue medication was allowed 20 min after the first dose.<BR/>34% of patients on dipyrone and 26.9% on flubiprofen took rescue anlagesia.</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:08:31 +0100" MODIFIED_BY="[Empty name]">
<P>PI = nonstandard 5 point categorical scale (0-4)</P>
<P>VAS (0-100mm) for PI<BR/>Global rating of treatment effect by the patient and the physician (4 point scale)</P>
<P>20 min SPID:<BR/>Dipyrone 2 g + hyoscine 20 mg=8.28<BR/>Flurbiprofen 150 mg=9.82<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 patient from the flubiprofen group did not meet the inclusion criteria.</P>
<P>Adverse effects:<BR/>Multiple dose AEs:<BR/>Number of patients with AEs:19.2% (5 patients) dipyrone; 11.5% (3 patients) <BR/>flurbiprofen</P>
<P>Local pain at injection site: dipyrone 2 g + hyoscine 20 mg (5); <BR/>flurbiprofen 150 mg (3).</P>
<P>QS = 3</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:08:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mora_x002d_Durban-1995">
<CHAR_METHODS MODIFIED="2011-04-20 16:08:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind,</P>
<P>No placebo group</P>
<P>Baseline PI =severe pain</P>
<P>Self assessment at t=0, 10, 20, 30, 45, 60 min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=90<BR/>Dipyrone 2 g + hyoscine 20 mg, n=26</P>
<P>Flurbiprofen 150 mg, n=64</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 2 g + hyoscine 20 mg; Flurbiprofen 150 mg</P>
<P>Single IM dose, 1 hr</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:08:52 +0100" MODIFIED_BY="[Empty name]">
<P>PI=nonstandard 5 point categorical scale (0-4)<BR/>VAS (0-100mm) for PI<BR/>Global rating by the patient and the physician (4 point scale)</P>
<P>Rescue medication was allowed 20 min after first dose. The final assessment prior to administration of rescue analgesic was used in the efficacy analysis .<BR/>Dipyrone=14/26<BR/>Flurbiprofen = 11/64</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multiple dose AEs:<BR/>Number of patients with AEs:<BR/>dipyrone 2 g + hyoscine 20 mg (21); flurbiprofen 150 mg (19).</P>
<P>Local pain at injection site: dipyrone 2 g + hyoscine 20 mg (21); flurbiprofen 150 mg (19).</P>
<P>Five patients were excluded: methodological mistake (2); did not meet the inclusion criteria (3)</P>
<P>QS=5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:09:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muriel-Villoria-1995">
<CHAR_METHODS>
<P>Randomised, double blind, </P>
<P>No placebo group</P>
<P>Baseline PI &gt;50 mm VAS </P>
<P>Self assessment at t = 0, 10, 20, 30, 60 min &amp; 2, 4, 6 hrs</P>
<P>IM + IV data<BR/>IM was contaminated and excluded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=84</P>
<P>Dipyrone 1 g, IV n=32</P>
<P>Dipyrone 2 g, IV n=30</P>
<P>Diclofenac 75 mg IV, n=22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 1 g, IV <BR/>Dipyrone 2 g, IV <BR/>Diclofenac 75 mg, IV</P>
<P>Single IV doses, 6hrs</P>
<P>Rescue analgesia (pethidine 100 mg IM)</P>
<P>After rescue the patients dropped out of study.<BR/>One patient on dipyrone 1 g IV took rescue.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:09:03 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment by patient &amp; observer.<BR/>PI (VAS 0-100mm) &amp; standard scale.</P>
<P>6 hrs SPID ( VAS) taken from Fig 1</P>
<P>1hr SPID:<BR/>Dipyrone 2g IV=448.32<BR/>Dipyrone 1g IV=386.21<BR/>Diclofenac 75 mg IV=407.37</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>AEs: <BR/>Single dose AEs.<BR/>5 patients had severe AEs.</P>
<P>Diclofenac 75 mg IV: sweating (1), vomiting (1)</P>
<P>QS=3</P>
<P>6 patients were excluded:<BR/>9 patients, PI &lt; 50 mm<BR/>5 patients, voluntary withdrawal<BR/>1 patient, lost ampoules<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:09:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanahuja-1990">
<CHAR_METHODS MODIFIED="2011-04-20 16:09:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind,</P>
<P>No placebo group</P>
<P>Baseline PI moderate &amp; severe pain</P>
<P>Self assessment at t=0, 15, 30, 60 &amp; 120 min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n=57<BR/>Dipyrone 2.5 g + pitofenone10 mg + fenpipramide bromomethylate 0.1mg (Baralgin) IV, n=28 </P>
<P>Diclofenac 75 mg IM, n=29</P>
<P>Withdrawals not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dipyrone 2.5 g + pitofenone10 mg + fenpipramide bromomethylate 0.1mg (Baralgin) IV</P>
<P>Diclofenac 75 mg IM</P>
<P>NB: route is different but blinded properly with placebos (double dummy)</P>
<P>Single IM / IV doses, 2 hrs</P>
<P>Remedication allowed 30 min after first dose if pain persisted or PI&gt;2 (same drug <BR/>as first dose ).<BR/>Also was allowed a third dose 30 min after the second one (morphine) if pain persisted or PI&gt;2.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>PI (standard categorical scale ) 4 point scale (0-3)</P>
<P>15 min SPID:</P>
<P>Baralgin (dipyrone combination) IV=0.3095</P>
<P>Diclofenac 75 mg IM = 0.359</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>AEs:<BR/>Multiple dose AEs:<BR/>Dipyrone (first dose) n=1 </P>
<P>No AEs were observed on the second dose.</P>
<P>Sweating: Baralgin, n=1</P>
<P>Local pain at injection site:<BR/>Baralgin, n=1</P>
<P>QS=3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-20 16:09:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stankov-1994">
<CHAR_METHODS MODIFIED="2011-04-20 16:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind,</P>
<P>No placebo group</P>
<P>Baseline PI - severe</P>
<P>Self assessment at t=0, 10, 20, 30, 50,70, 90 &amp; 120 min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=104</P>
<P>Dipyrone 2.5 g, n=36</P>
<P>Tramadol 100 mg, n=35</P>
<P>Butylscopolamine 20 mg, n=33</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-28 14:30:31 +0100" MODIFIED_BY="Sheena Derry">
<P>Dipyrone 2.5 g</P>
<P>Tramadol 100 mg</P>
<P>Butylscopolamine 20 mg</P>
<P>Single IV dose, 2hrs</P>
<P>Remedication was allowed after 20 min; the last available pain measurement before the second injection was carried forward to the end of the study period.</P>
<P>Patients who remedicated during the 2 hr observation period were withdrawn from the study.<BR/>Dipyrone=5<BR/>Tramadol=13</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 16:09:42 +0100" MODIFIED_BY="[Empty name]">
<P>PI: no pain - excruciating pain (5 points) nonstandard scale and VAS (0-100 mm)</P>
<P>PR: (5 point scale), almost standard wording.</P>
<P>Global assessment: (5 points) standard, by patient and investigator<BR/>Distinct PR &gt;10 mm shift on VAS.</P>
<P>VAS PID:<BR/>SPID 2hr:<BR/>Dipyrone 2.5 g IV=124.96 Dipyrone 2.5 g IV=56.86</P>
<P>VAS PID:<BR/>SPID 1hr:<BR/>Tramadol 100 mg IV=95.46 Tramadol 100 mg IV=40.98<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Number of patients with AEs per group:<BR/>Single dose AEs:<BR/>butylscopolamine (2); <BR/>dipyrone (1); tramadol (4).</P>
<P>Number of AEs:<BR/>Blurred vision: tramadol (1)</P>
<P>Nausea &amp; vomiting: tramadol (1); dipyrone (1); butylscopolamine (1)</P>
<P>Dizziness/lightheadedness: dipyrone (1); tramadol (2)</P>
<P>QS=3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AE - adverse effect<BR/>IM - intramuscular<BR/>IV - intravenous<BR/>PI - pain intensity<BR/>PR - pain relief<BR/>QS - quality score<BR/>VAS - visual analog score</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arico-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised<BR/>Not blind<BR/>No assessment of baseline Pl</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benyajati-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised<BR/>Not blind<BR/>No data to extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borelli-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not blind<BR/>Included mild pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Campero-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data to extract - used nonstandard scale PR (4 point)<BR/>Assessment of PR by observer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-El-Sherif-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not blind<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galassi-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised<BR/>Included other pain conditions in analysis<BR/>No data to extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Indudhara-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not double blind<BR/>No data to extract<BR/>Did not define Pain Relief</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalil-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised<BR/>Not blind<BR/>No assessment of baseline PI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lehtonen-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single blind<BR/>No assessment of baseline Pl<BR/>No data to extract - Nonstandard scale</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marthak-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not double blind<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muriel-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate of Muriel Villoria 1995</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pardo-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pourrat-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data to extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Primus-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Arnau-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Comeri-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lloret-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lloret-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Martin-Carrasco-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Miralles-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mora_x002d_Durban-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mora_x002d_Durban-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Muriel-Villoria-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sanahuja-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stankov-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-28 14:32:54 +0100" MODIFIED_BY="Sheena Derry">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-05-28 14:32:43 +0100" MODIFIED_BY="Sheena Derry" NO="1">
<TITLE>Patients with at least 50% pain relief with single dose dipyrone - Intramuscular</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TH>
<P>No. of trials</P>
</TH>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Dose</P>
</TH>
<TH>
<P>Duration</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>Mean % of patients</P>
</TH>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Dipyrone combination</P>
</TD>
<TD>
<P>2g+hyoscine 20mg</P>
</TD>
<TD>
<P>20 minutes</P>
</TD>
<TD>
<P>37/90</P>
</TD>
<TD>
<P>42 (28 &amp; 48)</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Flurbiprofen</P>
</TD>
<TD>
<P>150mg</P>
</TD>
<TD>
<P>20 minutes</P>
</TD>
<TD>
<P>53/89</P>
</TD>
<TD>
<P>60 (36 &amp; 69)</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>1g</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>72/116</P>
</TD>
<TD>
<P>62</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>2g</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>80/124</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Pethidine</P>
</TD>
<TD>
<P>100mg</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>80/118</P>
</TD>
<TD>
<P>68</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Diclofenac*</P>
</TD>
<TD>
<P>75mg</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>100/143</P>
</TD>
<TD>
<P>70 (68 &amp; 82)</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone combination</P>
</TD>
<TD>
<P>1g+pitofenon 0.4mg+ fenpiverine 0.04mg</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>28/50</P>
</TD>
<TD>
<P>56</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Indomethacin</P>
</TD>
<TD>
<P>50mg</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>34/50</P>
</TD>
<TD>
<P>68</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Diclofenac</P>
</TD>
<TD>
<P>75mg</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>38/48</P>
</TD>
<TD>
<P>79</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>* Baralgin: dipyrone 2.5g plus pitofenon 10mg plus fenipramide bromethylate 0.1mg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-05-28 14:32:54 +0100" MODIFIED_BY="Sheena Derry" NO="2">
<TITLE>Patients with at least 50% pain relief with single dose dipyrone - Intravenous</TITLE>
<TABLE COLS="6" ROWS="18">
<TR>
<TH>
<P>No. of trials</P>
</TH>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Dose</P>
</TH>
<TH>
<P>Duration</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>Mean % of patients</P>
</TH>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Dipyrone combination</P>
</TD>
<TD>
<P>Baralgin*</P>
</TD>
<TD>
<P>15 minutes</P>
</TD>
<TD>
<P>30/46</P>
</TD>
<TD>
<P>63 (58 &amp; 67)</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Sublingual nifefipine</P>
</TD>
<TD>
<P>10mg</P>
</TD>
<TD>
<P>15 minutes</P>
</TD>
<TD>
<P>8/25</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Intramuscular diclofenac</P>
</TD>
<TD>
<P>75mg</P>
</TD>
<TD>
<P>15 minutes</P>
</TD>
<TD>
<P>22/29</P>
</TD>
<TD>
<P>47</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>1g</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>16/23</P>
</TD>
<TD>
<P>70</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>2.5g</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>23/25</P>
</TD>
<TD>
<P>91</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone combination</P>
</TD>
<TD>
<P>2.5g+hyoscine 20mg</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>21/25</P>
</TD>
<TD>
<P>85</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Hyoscine</P>
</TD>
<TD>
<P>20mg</P>
</TD>
<TD>
<P>30 minutes</P>
</TD>
<TD>
<P>6/23</P>
</TD>
<TD>
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone combination</P>
</TD>
<TD>
<P>2.5g+hyoscine 20mg</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>22/25</P>
</TD>
<TD>
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Ketorolac</P>
</TD>
<TD>
<P>30mg</P>
</TD>
<TD>
<P>1 hour</P>
</TD>
<TD>
<P>17/20</P>
</TD>
<TD>
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>2.5g</P>
</TD>
<TD>
<P>2 hours</P>
</TD>
<TD>
<P>32/36</P>
</TD>
<TD>
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Tramadol</P>
</TD>
<TD>
<P>100mg</P>
</TD>
<TD>
<P>2 hours</P>
</TD>
<TD>
<P>23/35</P>
</TD>
<TD>
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Butylscopalamine</P>
</TD>
<TD>
<P>20mg</P>
</TD>
<TD>
<P>2 hours</P>
</TD>
<TD>
<P>21/33</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>1g</P>
</TD>
<TD>
<P>6 hours</P>
</TD>
<TD>
<P>23/32</P>
</TD>
<TD>
<P>73</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Dipyrone</P>
</TD>
<TD>
<P>2g</P>
</TD>
<TD>
<P>6 hours</P>
</TD>
<TD>
<P>27/30</P>
</TD>
<TD>
<P>89</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Diclofenac</P>
</TD>
<TD>
<P>75mg</P>
</TD>
<TD>
<P>6 hours</P>
</TD>
<TD>
<P>18/22</P>
</TD>
<TD>
<P>82</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>* Baralgin: dipyrone 2.5g plus pitofenon 10mg plus fenipramide bromethylate 0.1mg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-28 14:28:48 +0100" MODIFIED_BY="Sheena Derry">
<APPENDIX ID="APP-01" MODIFIED="2008-05-28 14:28:48 +0100" MODIFIED_BY="Sheena Derry" NO="1">
<TITLE MODIFIED="2008-05-28 14:28:46 +0100" MODIFIED_BY="Sheena Derry">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-28 14:28:48 +0100" MODIFIED_BY="Sheena Derry">
<P>dipyrone OR (all brand names of dipyrone)<BR/>AND<BR/>(pain or analgesi*)</P>
<P>Relevant records were downloaded into Procite and the following search was used to detect reports on renal colic pain:<BR/>(colic or calculi or calculus or stone or stones)<BR/>AND<BR/>(renal or ureteral or ureteric)</P>
<P>The brand names used in the search strategy were: adolkin, afebrin, aminopyrine sulphonate, analgin, analginum, ascorfebrina, baralgin, dolemicin, dolo buscopan, huberdor, inalgon, lasain, metamizol, metamizole, metamizole sodium, methampyrone, natrium novaminsulfonicum, minalgin, neo meubrina, neu novalgin, neu novalgine, neuro-brachont, neuro-formatin S, nolotil, noramidaophenum, noraminophenazonum, norgesic, novalgina, novalgine, novamidazofen, optalgin, pirenil, pyrethane, sulpyrine, trisalgina (<LINK REF="REF-Reynolds-1993" TYPE="REFERENCE">Reynolds 1993</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>